1. 2274 Is there any role of adjuvant chemotherapy for T3N0M0 or T1N2M0 gastric cancer, stage II in 7th TNM but stage I in 6th TNM system?. (September 2015) Authors: Lee, H.J.; Lee, K.G.; Suh, Y.S.; Kong, S.H.; Oh, D.Y.; Im, S.A.; Bang, Y.J.; Yang, H.K. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S424 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2364 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib trial. (September 2015) Authors: Chung, H.C.; Arkenau, H.T.; Wyrwicz, L.; Oh, D.Y.; Lee, K.W.; Infante, J.R.; Chin, K.; Von Heydebreck, A.; Kang, Y.K.; Safran, H. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S457 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study. (September 2015) Authors: Yao, J.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.; Lincy, J.; Sachs, C.; Valle, J.; Delle Fave, G.; Van Cutsem, E.; Tesselaar, M.E.T.; Shimada, Y.; Oh, D.Y.; Strosberg, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S709 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma. (October 2022) Authors: Piha-Paul, S.; Oh, D.Y.; Garralda, E.; Vieito, M.; Huang, J.; Kirschbaum, M.; Villanona-Calero, M. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor. (October 2022) Authors: Schram, A.; Borad, M.; Sahai, V.; Kamath, S.; Kim, R.; Liao, C.Y.A.; Oh, D.Y.; Ponz-Sarvisé, M.; Yachnin, J.; Shell, S.A.; Cassier, P.; Dotan, E.; Florou, V.; Moreno, V.; Park, J.O.; Tai, D.; Schmidt-Kittler, O.; Ferté, C.; Goyal, L.; Subbiah, V. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Image Gallery: Squamous cell carcinoma on an untreated vitiligo lesion. (19th July 2018) Authors: Oh, D.Y.; Jung, K.E.; Koo, D.W.; Lee, J.S. Journal: British journal of dermatology Issue: Volume 179:Number 1(2018) Page Start: e2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Image Gallery: Squamous cell carcinoma on an untreated vitiligo lesion. (1st July 2018) Authors: Oh, D.Y.; Jung, K.E.; Koo, D.W.; Lee, J.S. Journal: British journal of dermatology Issue: Volume 179:Number 1(2018) Page Start: e2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoSphere study. (April 2018) Authors: Triulzi, T.; Di Cosimo, S.; Bianchini, G.; Pienkowski, T.; Im, Y.H.; Bianchi, G.V.; De Cecco, L.; Tseng, L.M.; Liu, M.C.; Lluch, A.; Semiglazov, V.; De la Haba-Rodriguez, J.; Oh, D.Y.; Poirier, B.; Pedrini, J.L.; Valagussa, P.; Tagliabue, E.; Gianni, L. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗